Word

TELDAZIA

Status

Pending

Status Code

661

Status Date

Tuesday, April 23, 2024

Serial Number

98210357

Mark Type

4

Filing Date

Thursday, October 5, 2023

Trademark Owner History

MURAL ONCOLOGY, INC. - 1st New Owner Before Publication
Alkermes Pharma Ireland Limited - Original Applicant

Classifications

5 Biopharmaceutical active substances, namely, pharmaceutical preparations and substances for the treatment of oncological-related diseases and disorders; Biological preparations for the treatment of cancer; Engineered fusion proteins for medical diagnostic and treatment purposes, namely, engineered fusion proteins created through the use of circular permutation technology; Engineered interleukin protein pharmaceutical preparations for use in optimizing patients' immune cellular response to prevent cancer-associated morbidity and mortality; Pharmaceutical preparations, namely, tumor-targeted immunotherapeutic fusion proteins for the treatment of cancer and cancer-related disorders; Cytokine inhibitory pharmaceutical and biological preparations for use in the treatment of oncology-related diseases and disorders; Biological and chemical immunotherapy preparations comprising anti-body-cytokine fusion protein pharmaceutical preparations for use in the medical treatment and prevention of cancer

1 Therapeutic proteins for use in the manufacture of pharmaceutical preparations

44 Providing educational information in the field of medication treatment for oncology to health care providers and patients, namely, providing information in the field of cancer prevention, screening, diagnosis and treatment

42 Research and development of medicines for use in the fields of oncology-related diseases and disorders; Protein engineering for others for use in the development of pharmaceuticals; Protein structure modifications for others for use in the development of pharmaceuticals, namely, conducting pharmaceutical research and development of engineered protein therapeutic pharmaceuticals and biopharmaceuticals; Conducting medical and scientific research in the fields of oncology-related diseases and disorders; Conducting clinical medical research for use in the field of cancerous diseases and disorders; Clinical research in the field of cancerous diseases and disorders in the nature of development of pharmaceuticals and biopharmaceuticals; Scientific research in the field of cancerous diseases and disorders in the nature of development of pharmaceuticals and biopharmaceuticals; Providing information and data about medical and scientific research and development in the fields of pharmaceuticals, biopharmaceuticals, clinical trials, therapeutic proteins, fusion proteins, and cancerous diseases and disorders; Providing websites featuring medical and scientific research information about pharmaceutical and biopharmaceutical drugs and their preparations; Cytokine engineering and cytokine research and development for use in the development of pharmaceuticals, namely, conducting pharmaceutical research, engineering and development in the fields of cancer, immunopharmaceuticals for use in the treatment of cancer and engineered cytokine therapeutic pharmaceuticals and bio-pharmaceuticals; Conducting scientific research for others in the field of cytokine biology for use in pharmaceutical research and development; Scientific research and development of immune modulating proteins for others for use in the development of pharmaceuticals; Scientific research and development of cytokine based biopharmaceutical treatments for oncology-related diseases and disorders; Conducting protein based therapeutic medical research and pharmaceutical development in the field of pharmaceuticals and biopharmaceuticals for the treatment of cancer and related diseases and disorders; Protein or cytokine based cancer immunotherapy research and development, namely, conducting pharmaceutical research and development in the field of cancer; Providing educational information in the field of medication treatment for oncology to health care providers and patients, namely, providing medical and scientific research information about clinical trials featuring pharmaceutical treatments in the field of oncology

Trademark Events

Oct 9, 2023

New Application Entered

Oct 13, 2023

New Application Office Supplied Data Entered

Jan 24, 2024

Non-Final Action Written

Jan 24, 2024

Non-Final Action E-Mailed

Jan 24, 2024

Notification Of Non-Final Action E-Mailed

Feb 28, 2024

Automatic Update Of Assignment Of Ownership

Jan 23, 2024

Assigned To Examiner

Apr 23, 2024

Correspondence Received In Law Office

Apr 23, 2024

Teas Response To Office Action Received

Apr 23, 2024

Teas/Email Correspondence Entered